Clinical trials recruiting for Advanced Non Small Cell Lung Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
  NCT07801508 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
  NCT07652736 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07154290 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
  NCT07090499 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
  NCT05482568 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
  NCT06043973 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
  NCT07668037 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
  NCT05504278 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
  NCT06868732 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
  NCT05099172 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 92 locations
• Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
  NCT06107374 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
  NCT07415005 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 770 locations
• Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
  NCT06731413 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
  NCT04886401 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• SSGJ-707 in Advanced Non-Small Cell Lung Cancer
  NCT06980272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
  NCT05777603 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  NCT07185997 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT07222566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 440 locations
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
  NCT02133196 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
  NCT06908993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations

Related conditions

Trials recruiting for Advanced Non Small Cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Advanced Non Small Cell Lung Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.